Sara Ferraro
About
Sara Ferraro is a scholar working on Infectious Diseases, Epidemiology and Toxicology.
According to data from OpenAlex, Sara Ferraro has authored 29 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 6 papers in Epidemiology and 5 papers in Toxicology. Recurrent topics in Sara Ferraro's work include SARS-CoV-2 and COVID-19 Research (6 papers), COVID-19 Clinical Research Studies (5 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Sara Ferraro is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (6 papers), COVID-19 Clinical Research Studies (5 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Sara Ferraro collaborates with scholars based in Italy and United States. Sara Ferraro's co-authors include Marco Tuccori, Irma Convertino, Corrado Blandizzi, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Fabrizio Maggi, Aurora Daniele, Ersilia Nigro and Luca Leonardi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Critical Care.
In The Last Decade
Sara Ferraro
26 papers receiving 351 citations
Peers
Sara Ferraro
Irma Convertino Italy
Sang Hee Woo South Korea
Sushil Sharma India
Faisal Minshawi Saudi Arabia
Giulia Valdiserra Italy
Emiliano Cappello Italy
Yolanda Augustin United Kingdom
Mingxuan Xie China
Yuwei Liu China
Jacky Man Chun Chan Hong Kong
Citations per year, relative to Sara Ferraro Sara Ferraro (= 1×)
peers
Irma Convertino
Countries citing papers authored by Sara Ferraro
Since
Specialization
Citations
This map shows the geographic impact of Sara Ferraro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Ferraro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Ferraro more than expected).
Fields of papers citing papers by Sara Ferraro
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sara Ferraro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Ferraro. The network helps show where Sara Ferraro may publish in the future.
Co-authorship network of co-authors of Sara Ferraro
This figure shows the co-authorship network connecting the top 25 collaborators of Sara Ferraro. A scholar is included among the top collaborators of Sara Ferraro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Ferraro. Sara Ferraro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ferraro, Sara, Emiliano Cappello, Marco Fornili, et al.. (2024). Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database. Drug Safety. 48(3). 217–231.
2.
Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2023). Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy. Frontiers in Pharmacology. 14. 1244486–1244486.
3.
Roberto, Giuseppe, Sara Ferraro, Massimo Franchini, et al.. (2023). Cases of acquired hemophilia A following COVID ‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy. Pharmacoepidemiology and Drug Safety. 32(6). 694–699.
4.
Convertino, Irma, Valentina Lorenzoni, Rosa Gini, et al.. (2023). Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals. 16(3). 465–465.
5.
Valdiserra, Giulia, Nadia Mores, Laura Sottosanti, et al.. (2023). Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation. SHILAP Revista de lepidopterología. 3. 1194683–1194683.
6.
Ferraro, Sara, Emiliano Cappello, Claudia Bartolini, et al.. (2023). Potential missed diagnoses of Crohn’s disease in tertiary care: impact on drug utilization and healthcare facilities use. European Journal of Gastroenterology & Hepatology. 35(11). 1263–1269.
7.
Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2022). Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert Opinion on Drug Discovery. 17(6). 531–546.
8.
Convertino, Irma, Rosa Gini, Massimiliano Cazzato, et al.. (2021). Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. Journal of Clinical Medicine. 10(24). 5743–5743.
9.
Tuccori, Marco, Rosa Gini, Giuseppe Turchetti, et al.. (2021). Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study. CINECA IRIS Institutial research information system (University of Pisa).
10.
Cucchiara, Federico, et al.. (2021). Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacological Research. 175. 105976–105976.
11.
Ferraro, Sara, et al.. (2021). GDM-complicated pregnancies: focus on adipokines. Molecular Biology Reports. 48(12). 8171–8180.
12.
Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2021). Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases. Scientific Reports. 11(1). 20314–20314.
13.
Convertino, Irma, Ersilia Lucenteforte, Rosa Gini, et al.. (2021). Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons. Clinical and Experimental Rheumatology. 39(4). 753–762.
14.
Convertino, Irma, Marco Tuccori, Sara Ferraro, et al.. (2020). Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 24(1). 331–331.
15.
Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2020). The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Safety. 43(8). 699–709.
16.
Campoli, Caterina, Sara Ferraro, Nunzio Salfi, et al.. (2020). Diffuse primary cutaneous infection by Alternaria alternata in a liver transplant recipient with pulmonary nocardiosis: Importance of prompt identification for clinical resolution. Medical Mycology Case Reports. 28. 42–45.
17.
Ferraro, Sara, Marco Tuccori, Irma Convertino, et al.. (2020). Olfactory and gustatory impairments in COVID‐19 patients: Role in early diagnosis and interferences by concomitant drugs. British Journal of Clinical Pharmacology. 87(5). 2186–2188.
18.
Ferraro, Sara, Luca Leonardi, Irma Convertino, Corrado Blandizzi, & Marco Tuccori. (2019). Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. Frontiers in Pharmacology. 10. 247–247.
19.
Ferraro, Sara, Luca Leonardi, Corrado Blandizzi, Irma Convertino, & Marco Tuccori. (2019). Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports. Drug Safety. 42(10). 1207–1208.
20.
Convertino, Irma, Stefano Salvadori, Sara Ferraro, et al.. (2018). Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis. Drug Safety. 42(3). 427–444.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Irma Convertino Breakdown of academic impact, for papers by Sang Hee Woo Breakdown of academic impact, for papers by Sushil Sharma Breakdown of academic impact, for papers by Faisal Minshawi Breakdown of academic impact, for papers by Giulia Valdiserra Breakdown of academic impact, for papers by Emiliano Cappello Breakdown of academic impact, for papers by Yolanda Augustin Breakdown of academic impact, for papers by Mingxuan Xie Breakdown of academic impact, for papers by Yuwei Liu Breakdown of academic impact, for papers by Jacky Man Chun Chan